Earnings Feed
Start Free
Home/Filings/4/0001855763-23-000008
4//SEC Filing

DOCHERTY JOHN MARTIN 4

Accession 0001855763-23-000008

CIK 0001348362other
View on SEC.govCompany Profile

Filed

Oct 29, 8:00 PM ET

Accepted

Oct 30, 12:47 PM ET

Size

12.6 KB

Accession

0001855763-23-000008

Insider Transaction Report

Form 4
Period: 2023-10-26
Lexaria Bioscience Corp.LEXX
DOCHERTY JOHN MARTIN
DirectorPresident
Transactions
  • Award

    Stock Options

    2023-10-26+30,000→ 124,668 total
    Exercise: $1.15From: 2023-10-26Exp: 2028-10-26→ Common Shares (30,000 underlying)
Holdings

  • Stock Options

    Exercise: $3.00From: 2021-06-08Exp: 2026-06-08→ Common Shares (18,334 underlying)
    49,668

  • common shares

    (indirect: Private Holding Company)
    54,075

  • Stock Options

    Exercise: $3.00From: 2021-09-01Exp: 2026-09-01→ Common Shares (15,000 underlying)
    64,668

  • Stock Options

    Exercise: $2.91From: 2022-08-29Exp: 2027-08-29→ Common Shares (30,000 underlying)
    94,668

  • Stock Options

    Exercise: $3.00From: 2020-04-23Exp: 2025-04-23→ Common Shares (13,334 underlying)
    13,334

  • Stock Options

    Exercise: $3.00From: 2021-04-26Exp: 2026-04-26→ Common Shares (18,000 underlying)
    31,334
Footnotes (4)
  • [F1]Repriced from $9.60 pursuant to shareholder approval received on May 9, 2023
  • [F2]Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023
  • [F3]Repriced from $7.08 pursuant to shareholder approval received on May 9, 2023
  • [F4]Repriced from $6.23 pursuant to shareholder approval received on May 9, 2023

Documents

1 file

Issuer

Lexaria Bioscience Corp.

CIK 0001348362

→
Entity typeother

Related Parties

1
  • filerCIK 0001638727

Filing Metadata

Form type
4
Filed
Oct 29, 8:00 PM ET
Accepted
Oct 30, 12:47 PM ET
Size
12.6 KB
View on SEC.gov